C S Wilson

Summary

Affiliation: University of New Mexico
Country: USA

Publications

  1. ncbi DNA topoisomerase IIalpha in multiple myeloma: a marker of cell proliferation and not drug resistance
    C S Wilson
    Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Mod Pathol 14:886-91. 2001
  2. ncbi Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy
    C S Wilson
    University of Arkansas for Medical Sciences, Department of Pathology, Mail Slot 502, 4301 West Markham Street, Little Rock, AR 72205, USA
    Br J Haematol 112:776-82. 2001
  3. ncbi Cytology and flow cytometry of malignant effusions of multiple myeloma
    H E Palmer
    Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Diagn Cytopathol 22:147-51. 2000
  4. ncbi Soft tissue masses in patients with multiple myeloma: a fine-needle aspiration study of 30 cases with flow cytometry and clinical correlation
    P Mukunyadzi
    Department of Pathology, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas 72205, USA
    Cancer 93:257-62. 2001
  5. ncbi Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions
    I B Bayer-Garner
    Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Mod Pathol 14:1052-8. 2001

Collaborators

Detail Information

Publications5

  1. ncbi DNA topoisomerase IIalpha in multiple myeloma: a marker of cell proliferation and not drug resistance
    C S Wilson
    Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Mod Pathol 14:886-91. 2001
    ..Highly proliferative tumors are most likely to be sensitive to chemotherapeutic protocols using anti-topo IIalpha agents...
  2. ncbi Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy
    C S Wilson
    University of Arkansas for Medical Sciences, Department of Pathology, Mail Slot 502, 4301 West Markham Street, Little Rock, AR 72205, USA
    Br J Haematol 112:776-82. 2001
    ..We conclude that in low to intermediately proliferative MM cases, cyclin D1 is probably upregulated by t(11;14), but an alternative mechanism is more probable in highly proliferative MM...
  3. ncbi Cytology and flow cytometry of malignant effusions of multiple myeloma
    H E Palmer
    Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Diagn Cytopathol 22:147-51. 2000
    ..Our results suggest that FCM and cytology of serous effusions in multiple myeloma patients are complementary and should be used in difficult cases. Diagn. Cytopathol. 2000;22:147-151...
  4. ncbi Soft tissue masses in patients with multiple myeloma: a fine-needle aspiration study of 30 cases with flow cytometry and clinical correlation
    P Mukunyadzi
    Department of Pathology, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas 72205, USA
    Cancer 93:257-62. 2001
    ..The objective of the current study was to examine ST masses in MM patients using FNA and to classify and determine the prognostic significance of MM in these lesions based on cytologic features...
  5. ncbi Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions
    I B Bayer-Garner
    Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Mod Pathol 14:1052-8. 2001
    ..Because syndecan-1 can act to regulate the activity of heparan-binding growth factors, these reservoirs of syndecan-1 may play a critical role in promoting myeloma pathogenesis, or in regeneration of the tumor after chemotherapy...